Skip to main content
Top
Published in: Drug Safety 8/2007

01-08-2007 | Original Research Article

Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care Organisation

Authors: Catherine B. Johannes, Najat Ziyadeh, Dr John D. Seeger, Ed Tucker, Christoph Reiter, Gerald Faich

Published in: Drug Safety | Issue 8/2007

Login to get access

Abstract

Background: Data on the incidence of serious allergic reactions to fluoroquinolone antibacterials are mainly derived from spontaneous reports that cannot be used to accurately estimate incidence.
Methods: This study estimated the drug-specific incidence of serious allergic reactions after fluoroquinolone, cephalosporin and phenoxymethylpenicillin potassium exposure, using claims for healthcare services with confirmation through medical record abstraction within a large health insurer database. Cohorts exposed to each antibacterial of interest (moxifloxacin, levofloxacin, ciprofloxacin, gatifloxacin, cephalosporins and penicillin) were identified, and followed for 14 days for anaphylaxis (9th revision of the International Classification of Diseases [ICD-9] code 995.0), other allergic drug reactions (ICD-9 995.2, 995.3) or cardiopulmonary resuscitation.
Results: The incidence per 10 000 first dispensings of any allergic diagnosis made in the hospital or emergency department was similar for moxifloxacin (4.3; 95% CI 3.5, 5.3), penicillin (4.7; 95% CI 3.8, 5.7) and ciprofloxacin (5.4; 95% CI 4.4, 6.5). The incidence for moxifloxacin was lower than that for levofloxacin (8.7; 95% CI 7.4, 10.0), gatifloxacin (6.7; 95% CI 5.6, 7.9) and the cephalosporins (7.5; 95% CI 6.3, 8.8). The incidence of anaphylaxis/anaphylactoid reactions after first dispensings was similar for the fluoroquinolones: 0.1 (95% CI 0.0, 0.3) for ciprofloxacin, 0.3 (95% CI 0.1, 0.5) for moxifloxacin, 0.3 (95% CI 0.1, 0.6) for gatifloxacin and 0.5 (95% CI 0.3, 0.9) for levofloxacin; and comparable with that of the cephalosporins (0.2; 95% CI 0.0, 0.4) and penicillin (0.1; 95% CI 0.0, 0.3).
Conclusions: Anaphylactic reactions were rare and their incidence did not differ substantially among the drug groups studied. By determining the occurrence of reactions following defined exposures, these results provide a context for the interpretation of spontaneous reports of allergic reactions.
Literature
1.
2.
go back to reference Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940–50PubMedCrossRef Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940–50PubMedCrossRef
3.
go back to reference Campi P, Pichler WJ. Quinolone hypersensitivity. Curr Opinion Allergy Immunol 2003; 3: 275–81CrossRef Campi P, Pichler WJ. Quinolone hypersensitivity. Curr Opinion Allergy Immunol 2003; 3: 275–81CrossRef
4.
go back to reference Lieberman PL. Chapter 83: Anaphylaxis and anaphylactoid reactions. In: Adkinson NF, Yunginger JW, Busse WW, et al., editors. Middleton’s allergy: principles and practice. 6th ed. St Louis (MO): Mosby, Inc., 2003 Lieberman PL. Chapter 83: Anaphylaxis and anaphylactoid reactions. In: Adkinson NF, Yunginger JW, Busse WW, et al., editors. Middleton’s allergy: principles and practice. 6th ed. St Louis (MO): Mosby, Inc., 2003
5.
go back to reference Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill, 2005 Braunwald E, Fauci AS, Kasper DL, et al., editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill, 2005
6.
go back to reference Muelleman RL, Tran TP. Chapter 113: Allergy, hypersensitivity, and anaphylaxis. In: Rosen’s emergency medicine: concepts and clinical practice. 5th ed. St Louis (MO): Mosby, Inc., 2002 Muelleman RL, Tran TP. Chapter 113: Allergy, hypersensitivity, and anaphylaxis. In: Rosen’s emergency medicine: concepts and clinical practice. 5th ed. St Louis (MO): Mosby, Inc., 2002
7.
go back to reference Smythe MA, Cappelletty DM. Anaphylactoid reaction to levofloxacin. Pharmacotherapy 2000; 20: 1520–3PubMedCrossRef Smythe MA, Cappelletty DM. Anaphylactoid reaction to levofloxacin. Pharmacotherapy 2000; 20: 1520–3PubMedCrossRef
8.
go back to reference Ho DY, Song JC, Wang CC. Anaphylactoid reaction to ciprofloxacin. Ann Pharmacother 2003; 37: 1018–23PubMedCrossRef Ho DY, Song JC, Wang CC. Anaphylactoid reaction to ciprofloxacin. Ann Pharmacother 2003; 37: 1018–23PubMedCrossRef
9.
go back to reference Klein JS, Yocum MW. Underreporting of anaphylaxis in a community emergency room. J Allergy Clin Immunol 1995; 95: 637–8PubMedCrossRef Klein JS, Yocum MW. Underreporting of anaphylaxis in a community emergency room. J Allergy Clin Immunol 1995; 95: 637–8PubMedCrossRef
10.
go back to reference Brown AFT, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001; 108: 861–6PubMedCrossRef Brown AFT, McKinnon D, Chu K. Emergency department anaphylaxis: a review of 142 patients in a single year. J Allergy Clin Immunol 2001; 108: 861–6PubMedCrossRef
11.
go back to reference Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Pt 2): 253–72SCrossRef Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Pt 2): 253–72SCrossRef
12.
go back to reference Assouad M, Willcourt RJ, Goodman PH. Anaphylactoid reactions to ciprofloxacin. Ann Internal Med 1995; 122: 396–7 Assouad M, Willcourt RJ, Goodman PH. Anaphylactoid reactions to ciprofloxacin. Ann Internal Med 1995; 122: 396–7
13.
go back to reference Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf 2006; 29(11): 1087–100PubMedCrossRef Sachs B, Riegel S, Seebeck J, et al. Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf 2006; 29(11): 1087–100PubMedCrossRef
14.
go back to reference Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989; 111: 1041–3PubMed Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med 1989; 111: 1041–3PubMed
15.
go back to reference Alemán AM, Quirce S, Cuesta J, et al. Anaphylactoid reaction caused by moxifloxacin. J Invest Allergol Clin Immunol 2002; 12: 67–8 Alemán AM, Quirce S, Cuesta J, et al. Anaphylactoid reaction caused by moxifloxacin. J Invest Allergol Clin Immunol 2002; 12: 67–8
16.
go back to reference Rothman KJ. Epidemiology an introduction. New York: Oxford University Press, 2000: 134 Rothman KJ. Epidemiology an introduction. New York: Oxford University Press, 2000: 134
17.
go back to reference Gilman AG, Goodman LS, Rall TW, Murad F. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company, 1985: 1135 Gilman AG, Goodman LS, Rall TW, Murad F. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company, 1985: 1135
Metadata
Title
Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care Organisation
Authors
Catherine B. Johannes
Najat Ziyadeh
Dr John D. Seeger
Ed Tucker
Christoph Reiter
Gerald Faich
Publication date
01-08-2007
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 8/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200730080-00007

Other articles of this Issue 8/2007

Drug Safety 8/2007 Go to the issue

Correspondence

The Authors’ Reply